Autoimmun gepatitning davolash prinsiplarini takomillashtirish.

Please use this identifier to cite or link to this item: http://repository.tma.uz/xmlui/handle/1/8068

Full metadata record

DC Field	Value	Language
dc.contributor.author	Tairova G.B., Umirov S.Y.	-
dc.date.accessioned	2023-05-28T08:10:43Z	-
dc.date.available	2023-05-28T08:10:43Z	-
dc.date.issued	2023-04	-
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/8068	-
dc.description.abstract	Autoimmun gepatitning 81-86% ini 1-toifa tashkil qiladi. U zardobda yadroga qarshi antitanalar (ANA) va silliq mushak antitanalari (SMA-silliq mushak antitanalari) mavjudligi bilan tavsiflanadi. Bemorlarning 70 foizi ayollardir. Kasallik har qanday yoshda paydo bo'lishi mumkin bo'lsada, ko'pincha 40 yoshdan kiyin sodir bo'ladi. Biroq, tashxis odatda 50-60 yoshda qo'yiladi. Bemorlarning 45 foizida boshqa autoimmun kasallik (masalan, autoimmun tiroidit, sinovit, yarali kolit) hamroh bo'lsa, a'zolarga xos (organga xos) autoantitanalarni topish ehtimoli past. Immunosupressiv terapiyaga (immunitet tizimini bostiradigan dorilar bilan davolash) javob odatda ijobiy bo'ladi.	en_US
dc.language.iso	other	en_US
dc.publisher	KLINIK LABORATOR DIAGNOSTIKADA INNOVATSION TEXNOLOGIYALARDAN FOYDALANISH, MUAMMOLAR VA YECHIMLAR	en_US
dc.relation.ispartofseries	№2;	-
dc.subject	Autoimmun gepatit, surunkali jigar hujayralari, kortikosteroid	en_US
dc.title	Autoimmun gepatitning davolash prinsiplarini takomillashtirish.	en_US
dc.type	Thesis	en_US
Appears in Collections:	Thesis, Articles

Files in This Item:

File	Description	Size	Format
Autoimmun gepatitning davolash prinsiplarini takomillashtirish..pdf		1.25 MB	Adobe PDF	View/Open

DSpace JSPUI